Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway

Oncogene volume 33, pages 702–712 (2014)Cite this article

Subjects

Abstract

MicroRNAs (miRNAs) have important roles in the initiation and progression of human cancer, but their role in head and neck cancer development and progression is not well defined. We aimed to determine whether specific miRNAs and their target mRNAs contribute to head and neck cancer pathogenesis and progression. To identify miRNAs associated with head and neck squamous cell carcinomas (HNSCCs), we analyzed HNSCC cell lines, normal head and neck tissues and normal keratinocytes by miRNA profiling; a group of differentially expressed miRNAs was identified, which includes miR-125b. Decreased expression of miR-125b is known to occur in epithelial cancers and many target mRNAs for this miR have been reported. We found decreased expression of miR-125b-1 and hypermethylation of its promoter in HNSCC compared with its non-malignant counterpart. The TACSTD2 (also known as TROP2) gene was identified and validated as a direct target of miR-125b-1. Abnormal expression of TACSTD2 cell-surface glycoprotein has been reported in most epithelial tumors, and the overexpressions of this mRNA and protein product has been considered a useful tumor marker. We report that miR-125b-1 causes mitogen-activated protein kinase pathway dysfunction through regulation of TACSTD2 expression. Thus, loss of miR-125b-1 may have a key role in the pathogenesis and progression of squamous cell carcinomas of head and neck and possibly of other tumors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10–29.

    Article  Google Scholar 

  2. Forastiere A, Koch W, Trotti A, Sidransky D . Head and neck cancer. N Eng J Med 2001; 345: 1890–1900.

    Article  CAS  Google Scholar 

  3. Mao L, Hong WK, Papadimitrakopoulou VA . Focus on head and neck cancer. Cancer Cell 2004; 5: 311–316.

    Article  CAS  Google Scholar 

  4. Calin GA, Croce CM . MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857–866.

    Article  CAS  Google Scholar 

  5. Croce CM . Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704–714.

    Article  CAS  Google Scholar 

  6. Liu CJ, Tsai MM, Hung PS, Kao SY, Liu TY, Wu KJ et al. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res 2010; 70: 1635–1644.

    Article  CAS  Google Scholar 

  7. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J . Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008; 68: 2094–2105.

    Article  CAS  Google Scholar 

  8. Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ . High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 2007; 6: 5.

    Article  Google Scholar 

  9. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065–7070.

    Article  CAS  Google Scholar 

  10. Henson BJ, Bhattacharjee S, O’Dee DM, Feingold E, Gollin SM . Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. Genes Chromosomes Cancer 2009; 48: 569–582.

    Article  CAS  Google Scholar 

  11. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 2009; 125: 345–352.

    Article  CAS  Google Scholar 

  12. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 2007; 26: 7590–7595.

    Article  CAS  Google Scholar 

  13. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 2008; 99: 1290–1295.

    Article  CAS  Google Scholar 

  14. Fong D, Spizzo G, Gostner JM, Gastl G, Moser P, Krammel C et al. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol 2008; 21: 186–191.

    Article  CAS  Google Scholar 

  15. Mühlmann G, Spizzo G, Gostner J, Zitt M, Maier H, Moser P et al. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol 2009; 62: 152–158.

    Article  Google Scholar 

  16. Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiwa N, Okazumi S et al. Serological identification of TROP2 by recombinant cDNA expression cloning using seram of patients with esophageal squamous cell carcinoma. Int J Cancer 2004; 112: 1029–1035.

    Article  CAS  Google Scholar 

  17. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M . Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 2006; 12: 3057–3063.

    Article  CAS  Google Scholar 

  18. Liu CG, Calin GA, Meloon B, Gamliel N, Sevignani C, Ferracin M et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci USA 2004; 101: 9740–9744.

    Article  CAS  Google Scholar 

  19. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793–1801.

    Article  CAS  Google Scholar 

  20. Cubas R, Zhang S, Li M, Chen C, Yao Q . Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer 2010; 9: 253.

    Article  Google Scholar 

  21. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA . Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998; 273: 18623–18632.

    Article  CAS  Google Scholar 

  22. Kikkawa N, Hanazawa T, Fujimura L, Nohata N, Suzuki H, Chazono H et al. miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). Br J Cancer 2010; 103: 877–884.

    Article  CAS  Google Scholar 

  23. Kimura S, Naganuma S, Susuki D, Hirono Y, Yamaguchi A, Fujieda S et al. Expression of microRNAs in squamous cell carcinoma of human head and neck and the esophagus: miR-205 and miR-21 are specific markers for HNSCC and ESCC. Oncol Rep 2010; 6: 1625–1633.

    Google Scholar 

  24. Lee Y, Yang X, Huang Y, Fan H, Zhang Q, Wu Y et al. Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol 2010; 6: e1000730.

    Article  Google Scholar 

  25. Hui AB, Lenarduzzi M, Krushel T, Waldron L, Pintilie M, Shi W et al. Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res 2010; 16: 1129–1139.

    Article  CAS  Google Scholar 

  26. Avissar M, Christensen BC, Kelsey KT, Marsit CJ . MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin Cancer Res 2009; 15: 2850–2855.

    Article  CAS  Google Scholar 

  27. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC . Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007; 282: 1479–1486.

    Article  CAS  Google Scholar 

  28. Xia HF, He TZ, Liu CM, Cui Y, Song PP, Jin XH et al. MiR-125b expression affects the proliferation and apoptosis of human glioma cells by targeting Bmf. Cell Physiol Biochem 2009; 23: 347–358.

    Article  CAS  Google Scholar 

  29. Liang L, Wong CM, Ying Q, Fan DN, Huang S, Ding J et al. MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology 2010; 52: 1731–1740.

    Article  CAS  Google Scholar 

  30. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA 2007; 104: 19983–19988.

    Article  CAS  Google Scholar 

  31. Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z et al. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer 2011; 128: 1758–1769.

    Article  CAS  Google Scholar 

  32. Yamamoto N, Uzawa K, Miya T, Watanabe T, Yokoe H, Shibahara T et al. Frequent allelic loss/imbalance on the long arm of chromosome 21 in oral cancer: evidence for three discrete tumor suppressor gene loci. Oncol Rep 1999; 6: 1223–1227.

    CAS  PubMed  Google Scholar 

  33. Yamada H, Yanagisawa K, Tokumaru S, Taguchi A, Nimura Y, Osada H et al. Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11-21 in human lung cancer. Genes Chromosomes Cancer 2008; 47: 810–818.

    Article  CAS  Google Scholar 

  34. Negrini M, Rasio D, Hampton GM, Sabbioni S, Rattan S, Carter SL et al. Definition and refinement of chromosome 11 regions of LOH in breast cancer: identification of a new region at 11q23-q24. Cancer Res 1995; 55: 3003–3007.

    CAS  PubMed  Google Scholar 

  35. Rasio D, Negrini M, Manenti G, Dragani T, Croce CM . Loss of heterozygosity at chromosome 11q in lung adenocarcinoma: identification of three independent regions. Cancer Res 1995; 55: 3988–3991.

    CAS  PubMed  Google Scholar 

  36. Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res 2011; 71: 3552–3562.

    Article  CAS  Google Scholar 

  37. Bueno MJ, Pérez de Castro I, Gómez de Cedrón M, Santos J, Calin GA, Cigudosa JC et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008; 6: 496–506.

    Article  Google Scholar 

  38. Nakanishi H, Nakamura T, Canaani E, Croce CM . ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation in human acute leukemias. Proc Natl Acad Sci USA 2007; 104: 14442–14447.

    Article  CAS  Google Scholar 

  39. Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev 2009; 23: 862–876.

    Article  CAS  Google Scholar 

  40. Gupta S, Davis RJ . MAP kinase binds to the NH2-terminal activation domain of c-Myc. FEBS Lett 1994; 353: 281–285.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Dr Kay Huebner (Ohio State University) for careful editing of this manuscript and Sharon Palko (Ohio State University) for administrative support.

Author contributions: HN and CMC designed research; HN, RC, and TK performed research; HN, CT, JP, CFC, SV, and CMC analyzed data; HN and CMC wrote the paper. All authors critically reviewed and edited the paper.

Author information

Author notes

  1. C Taccioli

    Present address: 2Current address: Department of Cancer Biology, Paul O’Gorman Cancer Institute, University College London, London WC1E 6B, UK.,

Authors and Affiliations

  1. 1Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA

    H Nakanishi, C Taccioli, J Palatini, C Fernandez-Cymering, R Cui, T Kim, S Volinia & C M Croce

Authors
  1. H Nakanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Taccioli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Palatini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Fernandez-Cymering
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Volinia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C M Croce
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C M Croce.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakanishi, H., Taccioli, C., Palatini, J. et al. Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway. Oncogene 33, 702–712 (2014). https://doi.org/10.1038/onc.2013.13

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2013.13

Keywords

This article is cited by

Search

Advanced search

Quick links